Related Experiment Video
Updated: Aug 5, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Management of Ulcerative Colitis after Mesalamine-Induced Myocarditis: Successful Treatment with Upadacitinib - A
Taro Tanaka1, Takatoshi Nakashima1, Mitsuo Kinugasa2
1Department of Gastroenterology, Akashi Medical Center, Akashi, Japan.
Introduction:
Mesalamine intolerance occurs in 5-10% of patients with ulcerative colitis (UC), while myocarditis is an extremely rare but potentially fatal complication. Optimal UC management after mesalamine-induced myocarditis remains unclear.
Case Presentation:
A man in his 30s with left-sided UC developed mesalamine-induced myocarditis 3 weeks after treatment initiation, confirmed by elevated troponin T, reduced ejection fraction (23%), and a positive drug-induced lymphocyte stimulation test. Cardiac function improved with corticosteroids; however, UC relapsed during steroid tapering. After multidisciplinary discussion and shared decision-making, upadacitinib was selected considering potential cardiac risk with anti-TNF therapy and the need to minimize corticosteroid exposure. Rapid clinical improvement was observed, and complete mucosal healing (Mayo endoscopic subscore 0) was confirmed at 6-month follow-up colonoscopy.
Conclusion:
This is the first reported case of UC complicated by mesalamine-induced myocarditis successfully treated with upadacitinib. Janus kinase inhibitors may represent a therapeutic option when conventional biologics are unsuitable in patients with severe mesalamine intolerance.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids